Compass Therapeutics Reports Positive Interim Phase 2 Data of CTX-009 in Combination with Paclitaxel in Biliary Tract Cancers
04 mai 2022 07h00 HE
|
Compass Therapeutics
CTX-009 Demonstrated a 42% Overall Response Rate (ORR) Based on 10 Partial Responses (PRs) in 24 Enrolled Patients CTX-009 Continues to be Well Tolerated, Consistent with the Phase 1 Studies ...
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
21 mars 2022 08h00 HE
|
Compass Therapeutics
Ended 2021 with $144.5 million in cash and cash equivalentsCTX-009 (DLL4 X VEGF-A bispecific antibody) Global Phase 2 study in patients with advanced biliary tract cancers (BTC) is progressing well;...
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
03 mars 2022 07h30 HE
|
Helsinn Healthcare S.A.
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S. Helsinn gains an exclusive...
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A)
20 janv. 2022 08h30 HE
|
Compass Therapeutics
BOSTON, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada
20 déc. 2021 08h03 HE
|
Helsinn Healthcare S.A.
Helsinn and Xediton sign exclusive license and distribution agreement for TRUSELTIQ™ (infigratinib) in Canada Lugano, Switzerland, and Mississauga, Ontario, 20 December 2021 – Helsinn Group...
PCI Biotech: Presentation of fimaChem for bile duct cancer at IPA masterclass series
08 nov. 2021 05h15 HE
|
PCI Biotech Holding ASA
Oslo (Norway), 8 November 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announced that the coordinating principal investigator for the RELEASE trial, Prof. Dr. Jörg...
PCI Biotech receives Orphan Drug Designation in South Korea for fimaporfin in the treatment of bile duct cancer
28 mai 2021 08h51 HE
|
PCI Biotech Holding ASA
Oslo, 28 May 2021 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that the Ministry of Food and Drug Safety (MFDS) in South Korea has granted Orphan Drug...
Biliary Tumor Market to Gain Traction in the Coming Years; Advancements in NuCana’s Breakthrough Pipeline Drug Will Boost the Market, says Fortune Business Insights
19 juin 2019 07h45 HE
|
Fortune Business Insights
Pune, June 19, 2019 (GLOBE NEWSWIRE) -- The global Biliary Tumor Market is likely to derive growth from increasing usage approvals in the forthcoming years. According to an upcoming report by...
Delcath Announces Acceptance of Abstract for Oral Presentation at ECIO 2019
08 févr. 2019 08h00 HE
|
Delcath Systems, Inc.
NEW YORK, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces...
Delcath Announces Enrollment of First Patient in ALIGN Trial
18 oct. 2018 08h00 HE
|
Delcath Systems, Inc.
The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma NEW YORK, Oct. ...